解放军医学院学报2017，Vol.38Issue(4)：354-356,3.DOI:10.3969/j.issn.2095-5227.2017.04.017
磷脂酰肌醇蛋白聚糖-3在肝细胞癌中作用的研究进展
Research advances in role of glypican-3 in hepatocellular carcinoma
摘要
Abstract
Glypican-3 belongs to the glypican family, and it has been identified as diagnostic molecule in hepatocellular carcinoma (HCC) due to its high expression in HCC cells and patients' serum. Additionally, data indicate that it plays an important role in the initiation and progression of HCC. Nowadays, GPC-3-targeted therapies, including antibodies, peptide vaccines, and genetic therapies (miRNA, shRNA, and siRNA) can inhibit tumor growth. In this review, we will summarize the molecular structure of GPC-3, and its role in pathogenesis, diagnosis, and targeted therapies in HCC and make further exploration of clinical implications of GPC-3 in HCC.关键词
磷脂酰肌醇蛋白聚糖-3/肝细胞癌/靶向治疗Key words
glypican-3/hepatocellular carcinoma/targeted therapy分类
医药卫生引用本文复制引用
周福波,于晓玲..磷脂酰肌醇蛋白聚糖-3在肝细胞癌中作用的研究进展[J].解放军医学院学报,2017,38(4):354-356,3.基金项目
国家自然科学基金项目(81471683) Supported by the National Natural Science Foundation of China (81471683) （81471683）
